| Literature DB >> 33603891 |
Andra-Iulia Suceveanu1, Ioan Sergiu Micu1, Gabriela-Izabela Baltatescu2, Lucian Cristian Petcu3, Nicolae Dobrin2, Costel Brinzan4, Cornelia Nitipir5, Laura Mazilu6, Florin Botea7, Vlad Herlea8, Felix Voinea9, Adrian Paul Suceveanu1.
Abstract
Epidemiological data regarding hepatocellular carcinoma (HCC) report unsatisfactory morbimortality rates despite the global efforts to decrease the incidence and prolong patient survival. Current guidelines lack diagnostic biomarkers to better characterize patients with HCC. We aimed to validate the overexpression of Survivin-1, tumor-associated glyocoprotein 72 (Tag-72), and HECT and RLD domain containing E3 ubiquitin protein ligase 5 (HERC5) as tissue biomarkers for HCC characterization in patients from our geographical area and to standardize a local biomarker panel to be introduced in the current management guideline. Thirty samples of histologically confirmed HCC were compared to an equal number of samples of benign tumors in terms of Survivin-1, TAG-72, and HERC5 overexpression. Student's t-test, Mann-Whitney U test and Chi-square test were used to find differences between the two studied groups and to compare the categorical variables. The discriminative power of Survivin-1, Tag-72, and HERC5 overexpression was assessed using ROC curves. The multivariate linear regression analysis revealed that Survivin, Tag-72, and HERC5 were significantly overexpressed in older male patients, with α-fetoprotein (AFP) >200 ng/dl, low serum albumin, as well as in patients with imaging features of portal thrombosis and ascites. The diagnostic performance of Survivin-1, Tag-72 and HERC5 tissue biomarkers for HCC characterization was superior to that of the gold-standard AFP. Our study results validate the overexpression of Survivin-1, Tag-72, and HERC5 as tissue biomarkers for HCC characterization in patients from our geographical region and could be standardized in the current HCC management guideline.Entities:
Keywords: HERC5; Survivin-1; Tag-72; hepatocellular carcinoma; immunohistochemistry; overexpression
Year: 2021 PMID: 33603891 PMCID: PMC7851649 DOI: 10.3892/etm.2021.9715
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447